leukemia
Autolus Reports Steady Progress for Aucatzyl's US Launch, Anticipating European Approvals in 2025
The firm also said its partner BioNTech won't exercise its option rights for the CD19- and CD22-directed CAR T-cell therapy candidate AUTO1/22.
Hemogenyx Begins Phase I Trial of CAR T-Cell Therapy in FLT3-Expressing AML
The trial will test four dose levels and include up to 18 patients with advanced, FLT3-expressing acute myeloid leukemia.
UK's NICE Approves Blincyto as Frontline Consolidation Treatment for Certain Leukemia Patients
Blincyto plus chemo was approved for adult patients with Ph-negative, CD19-positive, and MRD-negative B-cell precursor acute lymphoblastic leukemia.
Foundation Medicine, Sumitomo Pharma to Develop CDx for Acute Leukemia Treatment
The companies will use the FoundationOne Heme platform to identify patients with acute leukemia who have a KMT2A rearrangement or NPM1 mutations.
EC Approves Amgen's Blincyto as Consolidation Treatment for Certain Newly Diagnosed Leukemia Cases
The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.